Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
about
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmissionInnovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Interleukin-10/Ceftriaxone prevents E. coli-induced delays in sensorimotor task learning and spatial memory in neonatal and adult Sprague-Dawley ratsAnhedonic behavior in cryptochrome 2-deficient mice is paralleled by altered diurnal patterns of amygdala gene expression.Brain Rewarding Stimulation Reduces Extracellular Glutamate Through Glial Modulation in Medial Prefrontal Cortex of RatsAltered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.STAT3 controls IL6-dependent regulation of serotonin transporter function and depression-like behavior.Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice.Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.Irritable bowel syndrome: a microbiome-gut-brain axis disorder?Glutamatergic modulators: the future of treating mood disorders?Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action.Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorderGluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamineAberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisineCefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial.α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties.Novel glutamatergic agents for major depressive disorder and bipolar disorder.Glial Expression of the Caenorhabditis elegans Gene swip-10 Supports Glutamate Dependent Control of Extrasynaptic Dopamine SignalingGlial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disordersClavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in miceUp-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouseGliogenesis and glial pathology in depression.Antidepressant-like effects of intracerebroventricular FGF2 in rats.Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice.From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disordersRole of the major glutamate transporter GLT1 in nucleus accumbens core versus shell in cue-induced cocaine-seeking behaviorTargeting the glutamatergic system to develop novel, improved therapeutics for mood disordersCytisine-based nicotinic partial agonists as novel antidepressant compounds.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice.Targeting glutamatergic signaling for the development of novel therapeutics for mood disordersExcitatory amino acid transporters as potential drug targets.Overview of glutamatergic neurotransmission in the nervous system.Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.
P2860
Q26859198-34ED30D6-24A0-481D-84A2-1327059E735CQ26996411-5A947B36-35A7-43F1-B60D-EBF5A9534ED9Q30495627-8E5D9CE5-7848-4EB6-A76B-6740B9BE06E8Q30653524-68532380-40AF-4DD2-BB57-0CB8237993BEQ30756186-BF65E0DB-BB46-4048-8596-C6F93755F887Q33553152-CF8BDFFE-3EB3-4D5F-BBCA-26FB37D706A0Q33562339-A8A69FA4-60E0-4DD4-8E95-6217224DFF64Q33680438-5DC665A7-E77D-4A3C-BCB3-C0A8C90B2200Q34288391-15E3A5E0-2AEE-443E-8DC6-ED4063ED2BBAQ34366837-9C36C127-DB83-4526-8F5B-A2197CDC8579Q34398007-B27236A3-130C-4325-B652-C67695909D58Q34522617-89E41BE5-2D23-476C-A926-A6571D5756B4Q34588846-09673140-6F19-4F7B-B326-EE4D8254050FQ34729421-26A1DD81-C6A1-40C0-B4A7-AFF710CDE494Q35019375-026ECEF4-D781-475C-B734-B5437F07D171Q35089398-11D50039-BE34-4D8C-AF78-033C84CE4C4EQ35121068-090B7D97-429F-41D0-AF88-D002DA1A3214Q35581667-46FCA52F-8833-4112-97E6-7FC3FCED95D6Q35661119-775618A3-0D5D-45D0-989E-62DD845CD491Q35772934-F8BF59DC-5EB1-42DB-9388-483F37BA1A5EQ35944981-A86E6403-2183-47F6-B3EA-67FCAC9309CCQ35962611-F291AE25-AD22-4AED-AD0B-6985F9C02E7BQ36094287-9B96315D-1271-448A-84B7-01513962A9CBQ36387362-08AE81A2-549D-4849-B57C-666AE70A6BDFQ36581692-A6D0116E-2446-4023-98A8-00B5604CB227Q36713909-C0BFAFCA-0B11-4987-ABDB-B2E6D67A6B66Q36825936-2E07FC48-5530-4CA5-A117-6B0703457801Q36868670-55B3C0D1-853F-4875-BB3B-8548A5C713C9Q36906277-306625AF-FBE5-42E5-8C1C-4EC0C925C7BFQ36944201-72BD000F-50F3-4E68-A5B3-06E50780009FQ36959660-DD3B3048-D359-46D0-B46E-6F2C6346F80BQ37143117-983B64B8-9F4C-45AC-8DAD-FDA4A59B7C58Q37162147-6A677B3D-0B1D-4CE1-868F-A9FBA0EF2272Q37387700-E2B84CF2-DBFA-4F72-BCEB-E7369E8AACBFQ37455947-A7ADA1D4-2F02-4E02-B6D8-4236FB10C87CQ37481603-982A1F46-5F6B-4747-8325-EB2B42507015Q37489935-8605E652-2435-4C4A-A499-54B059546DB8Q37926162-7F3FD9CF-97A5-4244-92DB-99686CFC01BFQ38512084-D359A9A9-DDEC-46C4-AF91-D5FC158EF863Q38580123-8647E3B8-4F74-4AF0-BDA1-FBDE0443E14F
P2860
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@en
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@nl
type
label
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@en
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@nl
prefLabel
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@en
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@nl
P1476
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.
@en
P2093
Gerard Sanacora
Yann S Mineur
P304
P356
10.1016/J.BIOPSYCH.2006.04.037
P407
P577
2006-07-24T00:00:00Z